Last updated: July 19, 2026
What is the market position of Pharmalogic Holdings (Pharmalogic) in the US?
Pharmalogic Holdings is a pharmaceutical manufacturer and distributor brand associated with regulated drug products, with a business model that typically emphasizes (1) sourcing, (2) manufacturing/packaging and/or contract manufacturing, and (3) selling products into the US market. Competitive positioning depends on each product’s regulatory status (FDA approval type, or whether the product is an FDA-listed drug or reconstitution kit), its route of administration, and payer/contract access.
Which therapeutic areas and product categories define Pharmalogic’s competitive footprint?
A defensible competitive landscape requires mapping Pharmalogic’s US portfolio to:
- FDA-approved products (NDA/BLA or ANDA-derived products)
- ANDA generic or authorized-generic portfolios
- OTC vs Rx
- Specialty delivery systems (injectables, inhalation, oral solids with specific release profiles)
- Distribution scope (group purchasing organization access, hospital systems, wholesaler channels)
What revenue exposure is linked to generic vs branded risk?
Competitive risk diverges sharply by product class:
- Generic-like exposure faces rapid price erosion, label-driven competition, and Paragraph IV challenges.
- Brand-like exposure depends on patent exclusivity, REMS, and substitution barriers (rare for typical generic manufacturers).
- Injectables and complex products face higher manufacturing/IP barriers, fewer qualified generic entrants, and faster obsolescence risk tied to facility compliance.
How strong is the patent estate for Pharmalogic products and what patents protect its key drugs?
A full patent-coverage assessment requires a product-by-product Orange Book and litigation mapping (patent numbers, claims, listed patents, and expiration dates). That mapping determines:
- Whether Pharmalogic benefits from listed regulatory exclusivity (NCE/NDA 505(c)(3)(E) type exclusivity, BLA exclusivity, 30-month stay leverage, or later-listed patents)
- Whether Pharmalogic’s products face Paragraph IV generic entry risk
- Whether Pharmalogic’s portfolio is exposed to design-around through formulation and method-of-use workarounds
Which patents usually matter in Pharmalogic’s competitive set for generics?
For generic competitive sets, the critical items are:
- Composition-of-matter patents covering the API
- Formulation patents (salt form, polymorph, particle size, dissolution profile, excipients)
- Method-of-use patents (label indications, dosing regimens)
- Process/method patents (manufacturing controls, crystallization, sterile fill-finish methods)
- Device or combination patents for kits, delivery systems, and reconstitution systems
What is the Orange Book status of Pharmalogic’s products?
Orange Book status is determined per active ingredient and strength/dosage form with:
- Drug listing type (reference listed drug, approved generic, discontinued statuses)
- Patent listing list per NDA/ANDA and their scheduled expiration
- Whether there are delisted patents or “grandfathered” listings
When does Pharmalogic lose exclusivity for key products and what are the expiration timelines?
Exclusivity and expiration timing is driven by:
- Regulatory exclusivity (NCE, pediatric exclusivity, orphan drug exclusivity, 7.5/5/3-year frameworks for eligible drugs)
- Patent expirations (composition, formulation, method-of-use)
- Listed patent delistings and any patent term adjustments (PTA)
How do patent expiration and exclusivity interact in generic entry scenarios?
For competitive planning, the launch timeline typically follows:
- Patent expires or is invalidated
- Generic/authorized generic seeks regulatory approval under ANDA and attempts entry
- If Paragraph IV is filed, 30-month stay can delay approval or launch
- If settlement is reached, stay can be extended by agreement
How many Paragraph IV challenges exist against Pharmalogic-linked ANDAs and who files them?
Competitive risk often comes from ANDA challengers and the litigation track. The key metrics are:
- Number of Paragraph IV filings tied to Pharmalogic products’ NDA/ANDA reference listed drug
- Filing dates and whether they are tied to the same dosage forms and strengths
- Which firms are repeatedly challenging in the same therapeutic niche
- Settlement structure (agreed “launch-at” dates and non-infringement positions)
What generic entry risks exist for Pharmalogic products?
Risks cluster by:
- High-patent density drugs (more listed patents, higher litigation likelihood)
- Complex manufacturing drugs (injectables, controlled-release forms)
- Narrow therapeutic index drugs where bioequivalence and formulation design are harder
What patent litigation affects Pharmalogic and how do settlements shape entry dates?
Litigation intensity and settlement outcomes affect market access and pricing. The practical signals to model are:
- Case initiation dates and consolidated dockets
- Parties (ANDA filer versus NDA holder)
- Whether settlement triggers “carve-out” launch around specific strengths
- Whether settlement allows authorized generics or license terms
Which companies are challenging Pharmalogic-linked products in court?
Court challengers are identified by matching:
- ANDA filer names
- Patent suit captions
- Filed Paragraph IV certifications
- Later stipulations and consent decrees
Which formulations are protected by Pharmalogic’s IP, and are there design-around pathways?
For formulation-protected products, design-around can take the form of:
- Switching salt form or polymorph
- Altering excipient composition
- Changing particle size or dissolution profile
- Adjusting manufacturing process parameters
What dosage forms are most exposed to formulation workarounds?
Risk is higher in:
- Oral solid dosage with dissolution constraints
- Extended-release formulations
- Fixed-dose combinations without strong method-of-use barriers
Risk is lower in:
- Sterile injectables requiring validated aseptic processing
- Products with complex manufacturing controls tied to patent claims
How does Pharmalogic’s manufacturing and regulatory posture compare with top generic competitors?
A competitive edge often comes from:
- Facility compliance history and inspection outcomes
- Sterility and control strategies for injectables
- Supply reliability and lot-release performance
- Ability to scale manufacturing while maintaining CMC comparability
What manufacturing/IP barriers block generic entrants against Pharmalogic?
Common barriers:
- Narrowly claimed process patents
- Facility-specific validation or documented manufacturing controls
- Quality system and batch record controls that prevent “quick replication”
- Long lead-time raw material procurement constraints
What is the competitive landscape for Pharmalogic in the US distribution channel?
Commercial competition often occurs through:
- Wholesaler contracts and direct hospital procurement
- GPO contracting
- State Medicaid formularies and buy-and-bill dynamics for injectables
- Pharmacy benefit manager preferences for supply stability and rebates
Who are Pharmalogic’s closest commercial peers?
Peers typically fall into:
- Generic manufacturers with overlapping dosage forms
- Specialty injectables suppliers
- Authorized generic producers
- Contract manufacturing organizations that compete for the same customers
How does Pharmalogic compare with direct competitors on exclusivity duration and launch timing?
A defensible comparison uses:
- Orange Book patent life remaining by product
- Exclusivity end dates (regulatory and patent-based)
- Litigation/settlement-driven delay effects
- Risk-adjusted probability of generic launch at earliest permitted date
What licensing deals or partnerships influence Pharmalogic’s product access?
Licensing can shift competitive positioning by enabling:
- Access to branded technology or authorized distribution
- Product rights acquisition from NDA holders or other ANDA holders
- Cross-licensing that reduces launch litigation exposure
How do licensing structures change competitive outcomes?
Common structures:
- Authorized generic agreements with constrained launch dates
- Settlement agreements that license formulation/process tech
- Distribution-only agreements that diversify supply risk
Key Timelines and Decision Framework for Competitive Entry Against Pharmalogic
Because competitive risk is product-specific, the decision framework is built around structured timelines:
Generic entry timeline model (per product)
- T0: Patent filing / Orange Book listing (if newly listed patents)
- T1: First Paragraph IV filing date (if challengers appear)
- T2: 30-month stay expiration (or earlier if dismissal/invalidity)
- T3: Earliest commercial launch date (adjusted for settlement)
- T4: Subsequent patent expirations (if later-listed patents remain)
- T5: Loss of exclusivity (API, formulation, method-of-use all expired)
Market Position Scorecard: What determines whether Pharmalogic’s products keep share?
A practical competitive scorecard measures:
- Patent estate density and litigation history
- Regulatory status stability (no delistings, no withdrawal)
- Competitive approvals already on market (number of approved generics)
- Supply resilience (ability to maintain contracts and avoid shortages)
- Pricing power (GPO position, rebate structure, and tender frequency)
Key Takeaways
- Pharmalogic’s competitive strength is product-dependent and should be assessed through Orange Book patent listing density, expiration timelines, and litigation/Paragraph IV activity rather than company-level branding.
- The major drivers of future share loss are patent expirations, settlement-mediated launch dates, and the number of approved ANDA competitors.
- Formulation- and process-protected assets reduce generic design-around speed, while sterile injectables typically increase manufacturing barriers and entry qualification time.
FAQs
- How do Orange Book listed patents affect generic launch timing for competitors of Pharmalogic?
- What litigation milestones (Paragraph IV, 30-month stay, settlement launch dates) most influence earliest entry against Pharmalogic products?
- Which formulation patent types create the biggest design-around hurdles for generic applicants?
- How should an investment model incorporate manufacturing compliance and inspection risk for Pharmalogic’s product portfolio?
- What commercial indicators (GPO awards, tender frequency, rebate levels) best predict pricing pressure once new generics enter?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Paragraph IV Certifications and Patent Certifications (Hatch-Waxman-related guidance and background materials). U.S. Food and Drug Administration.
- FDA. Drug Approval and Safety Communications related to exclusivity and patent listing processes (Hatch-Waxman framework resources). U.S. Food and Drug Administration.
